I guess we will need to wait and see what the analysis review has to say. This quote is pretty serious and I wonder why this review wasn't done before now as none of this is really news. "Accordingly, the Company has engaged a specialised global healthcare intelligence group to undertake an analysis on the potential future risks to the addressable market for Presendin™ for IIH. The results of the analysis will be available in mid Q3 CY2023. The Board will then be in a position to fully assess the market opportunity for Presendin™ in IIH in light of new GLP-1RAs including Ozempic® and Wegovy® and whether to continue with the revised protocol change for the IIH EVOLVE Phase III clinical trial."
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-53
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable